Neriman Gokden
Concepts (329)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Neoplasms | 13 | 2021 | 195 | 2.750 |
Why?
| Carcinoma, Renal Cell | 13 | 2021 | 119 | 2.400 |
Why?
| Immunohistochemistry | 14 | 2021 | 1097 | 1.190 |
Why?
| Kidney Diseases | 8 | 2020 | 292 | 1.180 |
Why?
| PAX2 Transcription Factor | 4 | 2010 | 22 | 1.140 |
Why?
| Kidney Tubules | 7 | 2021 | 100 | 1.080 |
Why?
| Immunoglobulin Light Chains | 4 | 2017 | 100 | 0.860 |
Why?
| Kidney | 11 | 2014 | 828 | 0.810 |
Why?
| Neoplasms, Complex and Mixed | 1 | 2020 | 2 | 0.780 |
Why?
| Rhabdoid Tumor | 1 | 2020 | 8 | 0.770 |
Why?
| Stromal Cells | 1 | 2020 | 80 | 0.740 |
Why?
| Soft Tissue Neoplasms | 1 | 2020 | 65 | 0.720 |
Why?
| Immune Complex Diseases | 2 | 2008 | 9 | 0.630 |
Why?
| Sepsis | 7 | 2014 | 253 | 0.580 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2008 | 168 | 0.540 |
Why?
| Adenoma, Oxyphilic | 2 | 2010 | 16 | 0.470 |
Why?
| Acute Kidney Injury | 7 | 2013 | 404 | 0.470 |
Why?
| Adenoma | 2 | 2021 | 142 | 0.460 |
Why?
| Carcinoma, Papillary | 2 | 2010 | 65 | 0.450 |
Why?
| Renal Circulation | 5 | 2013 | 82 | 0.410 |
Why?
| Proteinuria | 2 | 2010 | 52 | 0.390 |
Why?
| Male | 35 | 2021 | 27350 | 0.390 |
Why?
| Glomerulonephritis, IGA | 1 | 2010 | 13 | 0.390 |
Why?
| Podocytes | 1 | 2010 | 24 | 0.380 |
Why?
| Middle Aged | 24 | 2021 | 13094 | 0.380 |
Why?
| Microcirculation | 5 | 2014 | 89 | 0.370 |
Why?
| Nephrectomy | 2 | 2010 | 93 | 0.370 |
Why?
| Microscopy, Electron, Transmission | 5 | 2014 | 87 | 0.370 |
Why?
| Antigens, Neoplasm | 2 | 2008 | 170 | 0.370 |
Why?
| Humans | 42 | 2023 | 54132 | 0.360 |
Why?
| Prostatic Neoplasms | 4 | 2010 | 411 | 0.360 |
Why?
| Neurofibromatosis 2 | 1 | 2009 | 6 | 0.360 |
Why?
| DNA Glycosylases | 1 | 2008 | 22 | 0.330 |
Why?
| Adult | 19 | 2023 | 14196 | 0.320 |
Why?
| Plasmacytoma | 2 | 2020 | 47 | 0.320 |
Why?
| Kidney Glomerulus | 1 | 2008 | 61 | 0.310 |
Why?
| Renal Insufficiency | 4 | 2013 | 138 | 0.310 |
Why?
| Lymph Nodes | 1 | 2010 | 282 | 0.310 |
Why?
| Hypercalcemia | 1 | 2007 | 42 | 0.300 |
Why?
| DNA Repair | 1 | 2008 | 201 | 0.300 |
Why?
| Alphapapillomavirus | 1 | 2006 | 16 | 0.290 |
Why?
| Diagnosis, Differential | 6 | 2021 | 1133 | 0.290 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 62 | 0.290 |
Why?
| Sensitivity and Specificity | 5 | 2011 | 925 | 0.290 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2006 | 17 | 0.290 |
Why?
| Female | 24 | 2023 | 28437 | 0.290 |
Why?
| Carcinoma | 2 | 2020 | 153 | 0.280 |
Why?
| Bone Density Conservation Agents | 1 | 2007 | 81 | 0.280 |
Why?
| Diphosphonates | 1 | 2007 | 94 | 0.280 |
Why?
| Urinary Bladder Neoplasms | 3 | 2014 | 171 | 0.280 |
Why?
| Hepatitis B | 1 | 2006 | 27 | 0.280 |
Why?
| DNA, Viral | 1 | 2006 | 142 | 0.280 |
Why?
| Imidazoles | 1 | 2007 | 143 | 0.280 |
Why?
| Prostatic Intraepithelial Neoplasia | 1 | 2005 | 6 | 0.270 |
Why?
| Biopsy | 6 | 2020 | 694 | 0.260 |
Why?
| Adenocarcinoma | 2 | 2010 | 428 | 0.260 |
Why?
| Skin Neoplasms | 2 | 2018 | 530 | 0.260 |
Why?
| Neoplasms, Multiple Primary | 1 | 2005 | 45 | 0.260 |
Why?
| Paraproteinemias | 2 | 2016 | 79 | 0.240 |
Why?
| Pheochromocytoma | 1 | 2023 | 38 | 0.230 |
Why?
| Adrenal Gland Neoplasms | 1 | 2023 | 54 | 0.230 |
Why?
| Predictive Value of Tests | 5 | 2021 | 1053 | 0.230 |
Why?
| Dermatofibrosarcoma | 1 | 2003 | 9 | 0.230 |
Why?
| Aged, 80 and over | 8 | 2017 | 3442 | 0.230 |
Why?
| Oncogene Proteins, Fusion | 1 | 2003 | 60 | 0.230 |
Why?
| Aged | 12 | 2021 | 10059 | 0.220 |
Why?
| Kidney Diseases, Cystic | 1 | 2021 | 20 | 0.200 |
Why?
| Cisplatin | 3 | 2012 | 354 | 0.200 |
Why?
| Immunoglobulin G | 2 | 2014 | 228 | 0.200 |
Why?
| Multiple Myeloma | 3 | 2017 | 3024 | 0.190 |
Why?
| Precancerous Conditions | 1 | 2021 | 93 | 0.190 |
Why?
| Carcinoma, Transitional Cell | 2 | 2012 | 53 | 0.190 |
Why?
| Qb-SNARE Proteins | 1 | 2019 | 6 | 0.180 |
Why?
| Neoplasms, Plasma Cell | 1 | 2020 | 32 | 0.180 |
Why?
| Qc-SNARE Proteins | 1 | 2019 | 9 | 0.180 |
Why?
| Actin Cytoskeleton | 1 | 2019 | 26 | 0.180 |
Why?
| Hepatic Stellate Cells | 1 | 2019 | 18 | 0.180 |
Why?
| Myofibroblasts | 1 | 2019 | 48 | 0.180 |
Why?
| Antineoplastic Agents | 3 | 2017 | 1295 | 0.170 |
Why?
| Cell Nucleus | 2 | 2010 | 205 | 0.170 |
Why?
| Neoplasm Metastasis | 2 | 2010 | 252 | 0.170 |
Why?
| Kidney Failure, Chronic | 1 | 2021 | 229 | 0.170 |
Why?
| Myoblasts | 1 | 2018 | 20 | 0.160 |
Why?
| Melanoma | 2 | 2018 | 315 | 0.150 |
Why?
| Synovitis | 1 | 2017 | 24 | 0.150 |
Why?
| Capillaries | 4 | 2014 | 58 | 0.150 |
Why?
| Eosinophilia | 1 | 2017 | 37 | 0.150 |
Why?
| Cell Proliferation | 1 | 2021 | 1099 | 0.150 |
Why?
| Retrospective Studies | 5 | 2012 | 6387 | 0.140 |
Why?
| Angiomyolipoma | 1 | 2016 | 10 | 0.140 |
Why?
| Thoracic Neoplasms | 1 | 2016 | 11 | 0.140 |
Why?
| Tuberous Sclerosis | 1 | 2016 | 37 | 0.140 |
Why?
| DNA, Neoplasm | 2 | 2008 | 172 | 0.130 |
Why?
| Tumor Suppressor Proteins | 1 | 2016 | 141 | 0.130 |
Why?
| Receptors, Lysosphingolipid | 1 | 2014 | 6 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 239 | 0.130 |
Why?
| Reactive Nitrogen Species | 3 | 2011 | 39 | 0.130 |
Why?
| Mice | 11 | 2019 | 6436 | 0.130 |
Why?
| Urothelium | 1 | 2014 | 23 | 0.130 |
Why?
| Hemangiosarcoma | 1 | 2014 | 18 | 0.130 |
Why?
| Neoplasm Staging | 3 | 2014 | 801 | 0.120 |
Why?
| Immunoglobulin kappa-Chains | 1 | 2014 | 31 | 0.120 |
Why?
| Rolipram | 1 | 2013 | 4 | 0.120 |
Why?
| Phosphodiesterase 4 Inhibitors | 1 | 2013 | 4 | 0.120 |
Why?
| Necrosis | 2 | 2012 | 207 | 0.120 |
Why?
| Glomerulonephritis, Membranous | 1 | 2014 | 37 | 0.120 |
Why?
| Molecular Targeted Therapy | 1 | 2014 | 130 | 0.120 |
Why?
| Microscopy, Electron | 2 | 2020 | 97 | 0.120 |
Why?
| Glomerular Filtration Rate | 4 | 2017 | 138 | 0.120 |
Why?
| Translocation, Genetic | 2 | 2005 | 286 | 0.110 |
Why?
| Sarcoidosis | 1 | 2013 | 44 | 0.110 |
Why?
| Cryoglobulinemia | 1 | 2012 | 12 | 0.110 |
Why?
| Livedo Reticularis | 1 | 2012 | 5 | 0.110 |
Why?
| Lipoprotein Lipase | 1 | 2012 | 15 | 0.110 |
Why?
| Prospective Studies | 2 | 2010 | 2607 | 0.110 |
Why?
| Metalloporphyrins | 1 | 2011 | 13 | 0.110 |
Why?
| Free Radical Scavengers | 1 | 2011 | 35 | 0.100 |
Why?
| Cellular Microenvironment | 1 | 2011 | 27 | 0.100 |
Why?
| Adrenal Cortex Neoplasms | 1 | 2011 | 7 | 0.100 |
Why?
| Tissue Array Analysis | 2 | 2011 | 50 | 0.100 |
Why?
| Myocardium | 2 | 2017 | 445 | 0.100 |
Why?
| Animals | 12 | 2019 | 14435 | 0.100 |
Why?
| Stilbenes | 1 | 2011 | 65 | 0.100 |
Why?
| Peritoneal Neoplasms | 1 | 2012 | 60 | 0.100 |
Why?
| Triglycerides | 1 | 2012 | 199 | 0.100 |
Why?
| Microscopy, Fluorescence | 2 | 2014 | 196 | 0.100 |
Why?
| Hematuria | 1 | 2010 | 24 | 0.100 |
Why?
| Ejaculatory Ducts | 1 | 2010 | 3 | 0.100 |
Why?
| Seminal Vesicles | 1 | 2010 | 12 | 0.100 |
Why?
| Fluorescent Antibody Technique | 1 | 2010 | 141 | 0.090 |
Why?
| Metalloendopeptidases | 1 | 2011 | 82 | 0.090 |
Why?
| Plasma Cells | 1 | 2012 | 238 | 0.090 |
Why?
| In Situ Hybridization | 2 | 2006 | 85 | 0.090 |
Why?
| Hemodynamics | 1 | 2011 | 291 | 0.090 |
Why?
| Prostate | 1 | 2010 | 112 | 0.090 |
Why?
| RNA, Messenger | 4 | 2012 | 1222 | 0.090 |
Why?
| Antioxidants | 1 | 2011 | 297 | 0.090 |
Why?
| Epithelial Cells | 2 | 2011 | 256 | 0.090 |
Why?
| Polymerase Chain Reaction | 2 | 2008 | 533 | 0.090 |
Why?
| Lymphatic Metastasis | 1 | 2010 | 253 | 0.090 |
Why?
| Iron Chelating Agents | 1 | 2008 | 12 | 0.080 |
Why?
| Fatal Outcome | 1 | 2009 | 225 | 0.080 |
Why?
| Ligation | 3 | 2014 | 66 | 0.080 |
Why?
| Nephritis, Interstitial | 1 | 2008 | 12 | 0.080 |
Why?
| Benzoates | 1 | 2008 | 22 | 0.080 |
Why?
| Microsatellite Repeats | 1 | 2008 | 47 | 0.080 |
Why?
| Survival Analysis | 3 | 2017 | 739 | 0.080 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2008 | 2 | 0.080 |
Why?
| Glomerular Mesangium | 1 | 2008 | 8 | 0.080 |
Why?
| Basement Membrane | 1 | 2008 | 22 | 0.080 |
Why?
| Loss of Heterozygosity | 1 | 2008 | 97 | 0.080 |
Why?
| Mice, Inbred C57BL | 5 | 2013 | 2021 | 0.080 |
Why?
| Triazoles | 1 | 2008 | 121 | 0.080 |
Why?
| Glomerular Basement Membrane | 1 | 2007 | 12 | 0.080 |
Why?
| Cell Membrane | 1 | 2008 | 279 | 0.080 |
Why?
| Kidney Pelvis | 1 | 2006 | 20 | 0.070 |
Why?
| Paraffin Embedding | 1 | 2006 | 56 | 0.070 |
Why?
| Prednisone | 1 | 2007 | 111 | 0.070 |
Why?
| Karyotyping | 3 | 2017 | 93 | 0.070 |
Why?
| Nephrotic Syndrome | 1 | 2006 | 21 | 0.070 |
Why?
| Heart Diseases | 1 | 2009 | 238 | 0.070 |
Why?
| Oxidative Stress | 1 | 2011 | 953 | 0.070 |
Why?
| Young Adult | 4 | 2021 | 4320 | 0.070 |
Why?
| Clofibric Acid | 1 | 2005 | 8 | 0.070 |
Why?
| Lipopolysaccharides | 1 | 2006 | 199 | 0.070 |
Why?
| Chromosomes, Human, Pair 7 | 1 | 2005 | 30 | 0.070 |
Why?
| Chromosomes, Human, Pair 2 | 1 | 2005 | 29 | 0.070 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2005 | 16 | 0.070 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2005 | 20 | 0.070 |
Why?
| Neurofibroma | 1 | 2005 | 16 | 0.070 |
Why?
| Fibroma | 1 | 2005 | 41 | 0.060 |
Why?
| Protein Synthesis Inhibitors | 1 | 2004 | 19 | 0.060 |
Why?
| Foot | 1 | 2005 | 51 | 0.060 |
Why?
| Anti-Bacterial Agents | 1 | 2011 | 816 | 0.060 |
Why?
| Glucocorticoids | 1 | 2007 | 276 | 0.060 |
Why?
| Biopsy, Needle | 1 | 2005 | 195 | 0.060 |
Why?
| Blood Pressure | 3 | 2011 | 586 | 0.060 |
Why?
| Endodeoxyribonucleases | 1 | 2004 | 55 | 0.060 |
Why?
| Adrenalectomy | 1 | 2023 | 34 | 0.060 |
Why?
| Adrenal Glands | 1 | 2023 | 40 | 0.060 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 142 | 0.060 |
Why?
| Vulva | 1 | 2003 | 18 | 0.060 |
Why?
| Groin | 1 | 2003 | 16 | 0.060 |
Why?
| RNA, Neoplasm | 1 | 2003 | 55 | 0.060 |
Why?
| Cytoplasm | 1 | 2003 | 106 | 0.060 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2004 | 209 | 0.060 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 165 | 0.060 |
Why?
| Biopsy, Fine-Needle | 1 | 2003 | 116 | 0.060 |
Why?
| Time Factors | 3 | 2014 | 3223 | 0.050 |
Why?
| Blotting, Western | 3 | 2012 | 685 | 0.050 |
Why?
| Neoplasm Invasiveness | 2 | 2014 | 294 | 0.050 |
Why?
| Blood Flow Velocity | 2 | 2013 | 115 | 0.050 |
Why?
| Sequence Analysis, DNA | 1 | 2003 | 277 | 0.050 |
Why?
| DNA, Mitochondrial | 1 | 2003 | 189 | 0.050 |
Why?
| Capillary Permeability | 2 | 2011 | 40 | 0.050 |
Why?
| Mass Screening | 1 | 2005 | 369 | 0.050 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 682 | 0.050 |
Why?
| Bone Neoplasms | 1 | 2003 | 191 | 0.050 |
Why?
| Hyperplasia | 1 | 2021 | 108 | 0.050 |
Why?
| Disease Models, Animal | 3 | 2013 | 1645 | 0.050 |
Why?
| Adolescent | 3 | 2014 | 6890 | 0.050 |
Why?
| Transcription Factors | 1 | 2004 | 619 | 0.050 |
Why?
| Clinical Laboratory Techniques | 1 | 2020 | 32 | 0.050 |
Why?
| Cell Differentiation | 2 | 2014 | 717 | 0.050 |
Why?
| Stress Fibers | 1 | 2019 | 5 | 0.050 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2021 | 277 | 0.050 |
Why?
| Actin Depolymerizing Factors | 1 | 2019 | 5 | 0.050 |
Why?
| rho-Associated Kinases | 1 | 2019 | 20 | 0.050 |
Why?
| Carbon Tetrachloride | 1 | 2019 | 20 | 0.050 |
Why?
| Liver | 2 | 2019 | 1246 | 0.050 |
Why?
| Heart Rate | 2 | 2011 | 353 | 0.050 |
Why?
| RNA, Viral | 1 | 2020 | 142 | 0.040 |
Why?
| Nitrites | 2 | 2011 | 39 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2019 | 127 | 0.040 |
Why?
| Cell Separation | 1 | 2019 | 108 | 0.040 |
Why?
| Nitrates | 2 | 2011 | 49 | 0.040 |
Why?
| Neutrophil Infiltration | 2 | 2012 | 29 | 0.040 |
Why?
| Treatment Outcome | 3 | 2017 | 5596 | 0.040 |
Why?
| Child, Preschool | 2 | 2011 | 4132 | 0.040 |
Why?
| RNA Interference | 1 | 2019 | 195 | 0.040 |
Why?
| Actins | 1 | 2019 | 134 | 0.040 |
Why?
| Cecum | 2 | 2011 | 72 | 0.040 |
Why?
| RNA, Small Interfering | 1 | 2019 | 254 | 0.040 |
Why?
| Liver Neoplasms | 1 | 2003 | 353 | 0.040 |
Why?
| Cell Movement | 1 | 2019 | 276 | 0.040 |
Why?
| Cell Dedifferentiation | 1 | 2018 | 9 | 0.040 |
Why?
| Antibodies, Monoclonal | 1 | 2003 | 560 | 0.040 |
Why?
| Wound Healing | 1 | 2019 | 231 | 0.040 |
Why?
| Kidney Function Tests | 1 | 2017 | 61 | 0.040 |
Why?
| Liver Cirrhosis | 1 | 2019 | 216 | 0.040 |
Why?
| Microscopy, Video | 2 | 2007 | 17 | 0.040 |
Why?
| Reactive Oxygen Species | 2 | 2011 | 494 | 0.040 |
Why?
| Lung Neoplasms | 1 | 2003 | 631 | 0.040 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2007 | 83 | 0.040 |
Why?
| Acute Disease | 2 | 2008 | 405 | 0.040 |
Why?
| Mutation | 1 | 2003 | 1499 | 0.040 |
Why?
| Cell Line | 1 | 2019 | 1166 | 0.040 |
Why?
| Cardiomyopathy, Restrictive | 1 | 2016 | 5 | 0.040 |
Why?
| Risk Factors | 1 | 2005 | 3936 | 0.030 |
Why?
| Cysts | 1 | 2016 | 48 | 0.030 |
Why?
| Genomics | 1 | 2017 | 309 | 0.030 |
Why?
| Oxadiazoles | 1 | 2014 | 13 | 0.030 |
Why?
| Bone Marrow | 1 | 2017 | 415 | 0.030 |
Why?
| Immunotherapy | 1 | 2017 | 260 | 0.030 |
Why?
| Permeability | 1 | 2014 | 87 | 0.030 |
Why?
| Punctures | 1 | 2014 | 57 | 0.030 |
Why?
| Thiophenes | 1 | 2014 | 40 | 0.030 |
Why?
| Antigen-Antibody Complex | 1 | 2014 | 39 | 0.030 |
Why?
| Terminology as Topic | 1 | 2014 | 71 | 0.030 |
Why?
| Pyrazoles | 1 | 2014 | 112 | 0.030 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 82 | 0.030 |
Why?
| Pyridines | 1 | 2014 | 137 | 0.030 |
Why?
| Granuloma | 1 | 2013 | 46 | 0.030 |
Why?
| Bone Marrow Examination | 1 | 2012 | 12 | 0.030 |
Why?
| Receptors, Lipoprotein | 1 | 2012 | 8 | 0.030 |
Why?
| Angiopoietins | 1 | 2012 | 8 | 0.030 |
Why?
| Azo Compounds | 1 | 2012 | 12 | 0.030 |
Why?
| Peroxisome Proliferator-Activated Receptors | 1 | 2012 | 16 | 0.030 |
Why?
| Signal Transduction | 1 | 2019 | 1754 | 0.030 |
Why?
| Plasma Exchange | 1 | 2012 | 33 | 0.030 |
Why?
| Coloring Agents | 1 | 2012 | 84 | 0.030 |
Why?
| Adipose Tissue, White | 1 | 2012 | 40 | 0.030 |
Why?
| Immunosuppressive Agents | 1 | 2014 | 249 | 0.030 |
Why?
| Epithelium | 1 | 2011 | 70 | 0.030 |
Why?
| Cystectomy | 1 | 2012 | 51 | 0.030 |
Why?
| Prognosis | 1 | 2017 | 2116 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2011 | 89 | 0.030 |
Why?
| Superoxide Dismutase | 1 | 2011 | 125 | 0.030 |
Why?
| Telemetry | 1 | 2011 | 36 | 0.030 |
Why?
| Peritonitis | 1 | 2011 | 33 | 0.020 |
Why?
| Multiple Organ Failure | 1 | 2011 | 56 | 0.020 |
Why?
| Child | 2 | 2016 | 7312 | 0.020 |
Why?
| Hydroxamic Acids | 1 | 2011 | 47 | 0.020 |
Why?
| Vasodilator Agents | 1 | 2011 | 111 | 0.020 |
Why?
| Hypothermia | 1 | 2011 | 41 | 0.020 |
Why?
| Fluid Therapy | 1 | 2011 | 87 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2014 | 1478 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2011 | 93 | 0.020 |
Why?
| Disease Progression | 1 | 2013 | 915 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2011 | 384 | 0.020 |
Why?
| United States | 1 | 2021 | 5172 | 0.020 |
Why?
| Animals, Newborn | 1 | 2011 | 397 | 0.020 |
Why?
| Body Weight | 1 | 2012 | 583 | 0.020 |
Why?
| Membrane Proteins | 1 | 2012 | 391 | 0.020 |
Why?
| Gene Expression | 1 | 2012 | 667 | 0.020 |
Why?
| Iron Overload | 1 | 2008 | 11 | 0.020 |
Why?
| Skin | 1 | 2012 | 469 | 0.020 |
Why?
| Infant, Newborn | 1 | 2016 | 2901 | 0.020 |
Why?
| Eosinophils | 1 | 2008 | 36 | 0.020 |
Why?
| Drug Hypersensitivity | 1 | 2008 | 41 | 0.020 |
Why?
| Cells, Cultured | 1 | 2012 | 1755 | 0.020 |
Why?
| Myelodysplastic Syndromes | 1 | 2008 | 79 | 0.020 |
Why?
| Erythrocyte Transfusion | 1 | 2008 | 74 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2011 | 1676 | 0.020 |
Why?
| NADP | 1 | 2006 | 27 | 0.020 |
Why?
| Blood Urea Nitrogen | 1 | 2006 | 51 | 0.020 |
Why?
| Lysine | 1 | 2007 | 100 | 0.020 |
Why?
| Creatinine | 1 | 2006 | 170 | 0.020 |
Why?
| Nuclease Protection Assays | 1 | 2005 | 2 | 0.020 |
Why?
| Chemokine CCL5 | 1 | 2005 | 5 | 0.020 |
Why?
| Receptors, CCR5 | 1 | 2005 | 9 | 0.020 |
Why?
| Receptors, CCR1 | 1 | 2005 | 10 | 0.020 |
Why?
| Receptors, Chemokine | 1 | 2005 | 13 | 0.020 |
Why?
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 72 | 0.020 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 42 | 0.020 |
Why?
| Stress, Physiological | 1 | 2006 | 194 | 0.020 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 75 | 0.020 |
Why?
| PPAR alpha | 1 | 2005 | 65 | 0.020 |
Why?
| Muscle Neoplasms | 1 | 2005 | 21 | 0.020 |
Why?
| Chemokines | 1 | 2005 | 96 | 0.020 |
Why?
| Prostatectomy | 1 | 2005 | 87 | 0.020 |
Why?
| Nitric Oxide | 1 | 2007 | 298 | 0.020 |
Why?
| Chromosome Mapping | 1 | 2005 | 176 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 318 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2007 | 456 | 0.020 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 88 | 0.020 |
Why?
| Rats | 1 | 2011 | 3435 | 0.020 |
Why?
| Ligands | 1 | 2004 | 233 | 0.010 |
Why?
| Pyrimidines | 1 | 2005 | 196 | 0.010 |
Why?
| Cell Death | 1 | 2004 | 228 | 0.010 |
Why?
| Kidney Tubules, Proximal | 1 | 2004 | 134 | 0.010 |
Why?
| Antigens, CD | 1 | 2005 | 242 | 0.010 |
Why?
| NF-kappa B | 1 | 2005 | 336 | 0.010 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2005 | 436 | 0.010 |
Why?
| Models, Genetic | 1 | 2003 | 209 | 0.010 |
Why?
| Infant | 1 | 2011 | 3797 | 0.010 |
Why?
| Mice, Knockout | 1 | 2005 | 941 | 0.010 |
Why?
| Base Sequence | 1 | 2003 | 732 | 0.010 |
Why?
| Cytokines | 1 | 2005 | 678 | 0.010 |
Why?
|
|
Gokden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|